AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Saving... (p-- Community programs 6 percent .....)

AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs

Date:7/23/2008

p>-- Community programs 6 percent

-- Family/friend 5 percent

-- Other/don't know 24 percent

Patients who cited advertising said they learned of the program from a variety of newspaper, radio and television ads. AstraZeneca was the first in the industry to promote its prescription savings programs in its product television ads. Television ads for NEXIUM started carrying the message in April 2005, and all of AstraZeneca's product television ads have included the information since then. Previous research shows that including this information in our advertising significantly raised awareness and the impact of AstraZeneca's patient assistance program among the public.

AstraZeneca has offered prescription savings programs side by side with its medicines for three decades and now offers one of the industry's most generous programs. People without insurance who earn up to $30,000 for an individual and $60,000 for a family of four may be eligible for help from AstraZeneca.

In 2007 alone, AstraZeneca helped nearly half a million people fill 2.8 million prescriptions, resulting in more than $500 million of savings to patients. AstraZeneca offers help under the AZ&Me Prescription Savings programs, including support for people without insurance, people with Medicare Part D and a third program that provides medicines to healthcare facilities.

Patients can learn more about the AZ&Me Prescription Savings program at http://www.azandme.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
4. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
5. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
6. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
7. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
8. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
9. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
10. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca

Post Your Comments:

AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Saving...(p-- Community programs 6 percent .....)